🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 07/03/2017 | 90,14 | 91,70 | 89,77 | 91,32 | +0,45% | 2,14% | 1.960.700 |
| 06/03/2017 | 89,75 | 91,68 | 88,87 | 90,91 | +0,80% | 3,13% | 1.587.700 |
| 03/03/2017 | 89,54 | 90,39 | 88,95 | 90,19 | +0,33% | 1,61% | 1.422.600 |
| 02/03/2017 | 89,94 | 91,06 | 89,57 | 89,89 | -0,47% | 1,66% | 1.060.900 |
| 01/03/2017 | 91,80 | 92,26 | 89,83 | 90,31 | -0,34% | 2,65% | 2.089.400 |
| 28/02/2017 | 89,17 | 91,95 | 88,79 | 90,62 | +1,93% | 3,54% | 2.401.900 |
| 27/02/2017 | 86,19 | 88,95 | 85,84 | 88,90 | +3,29% | 3,61% | 2.073.700 |
| 24/02/2017 | 85,73 | 86,11 | 84,62 | 86,07 | +0,40% | 1,74% | 1.406.800 |
| 23/02/2017 | 86,20 | 86,63 | 84,39 | 85,73 | -0,07% | 2,60% | 890.800 |
| 22/02/2017 | 86,55 | 87,33 | 85,72 | 85,79 | -0,88% | 1,86% | 1.263.200 |
| 21/02/2017 | 88,34 | 89,00 | 86,01 | 86,55 | -2,02% | 3,38% | 1.665.300 |
| 17/02/2017 | 87,69 | 88,98 | 86,90 | 88,33 | +0,72% | 2,37% | 1.429.000 |
| 16/02/2017 | 89,62 | 89,94 | 87,05 | 87,70 | -1,87% | 3,22% | 1.322.200 |
| 15/02/2017 | 88,69 | 89,46 | 88,34 | 89,37 | +0,52% | 1,26% | 1.329.800 |
| 14/02/2017 | 87,89 | 89,26 | 87,34 | 88,91 | +1,36% | 2,18% | 2.321.600 |
| 13/02/2017 | 88,39 | 88,64 | 87,25 | 87,72 | -0,49% | 1,57% | 1.123.500 |
| 10/02/2017 | 89,21 | 89,64 | 87,89 | 88,15 | -1,25% | 1,96% | 1.633.800 |
| 09/02/2017 | 88,09 | 89,42 | 87,70 | 89,27 | +1,77% | 1,95% | 1.520.000 |
| 08/02/2017 | 86,27 | 87,80 | 85,79 | 87,72 | +1,01% | 2,33% | 1.310.100 |
| 07/02/2017 | 87,29 | 88,12 | 86,07 | 86,84 | -0,66% | 2,35% | 1.285.200 |
| 06/02/2017 | 86,22 | 87,98 | 85,73 | 87,42 | +0,80% | 2,61% | 1.423.800 |
| 03/02/2017 | 87,10 | 87,27 | 85,77 | 86,73 | +0,01% | 1,72% | 1.226.800 |
| 02/02/2017 | 85,99 | 86,90 | 85,16 | 86,72 | +0,56% | 2,02% | 1.290.800 |
| 01/02/2017 | 85,98 | 86,43 | 84,33 | 86,24 | +0,43% | 2,44% | 1.754.700 |
| 31/01/2017 | 83,77 | 85,95 | 82,66 | 85,87 | +1,77% | 3,93% | 2.418.400 |
| 30/01/2017 | 87,07 | 87,07 | 83,78 | 84,38 | -3,42% | 3,78% | 1.805.700 |
| 27/01/2017 | 85,62 | 87,50 | 85,10 | 87,37 | +2,39% | 2,80% | 1.861.100 |
| 26/01/2017 | 85,75 | 87,91 | 84,05 | 85,33 | +0,16% | 4,50% | 2.531.700 |
| 25/01/2017 | 82,55 | 85,62 | 82,35 | 85,19 | +3,59% | 3,96% | 2.654.600 |
| 24/01/2017 | 81,42 | 82,60 | 80,55 | 82,24 | +1,03% | 2,52% | 1.366.600 |